✦ LIBER ✦

High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma

✍ Scribed by Don M. Benson Jr.; Patrick J. Elder; Thomas S. Lin; William Blum; Sam Penza; Belinda Avalos; Edward Copelan; Sherif S. Farag

Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 192 KB
Volume: 31
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2006.09.021

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Busulfan, cyclophosphamide, and etoposid

Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma

✍ Christopher R. Cogle; Jan S. Moreb; Helen L. Leather; Katarzyna J. Finiewicz; Sh 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

## Abstract Autologous stem cell transplantation (ASCT) has enabled the use of high‐dose alkylating agents either as a single agent or in combination with other cytotoxic agents and/or total body irradiation (TBI) for the treatment of multiple myeloma. Despite improved complete remission rates, rel

Comparison of high-dose melphalan with a

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma

✍ Athanasios Anagnostopoulos; Ana Aleman; Gregory Ayers; Michele Donato; Richard C 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

## Abstract ## BACKGROUND High‐dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as part of the initial treatment regimen improves progression‐free survival (PFS) and overall survival (OS) for patients with multiple myeloma. The optimal preparative regimen for patients with

A Phase II study of 153Sm-EDTMP and high

A Phase II study of 153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

✍ Angela Dispenzieri; Gregory A. Wiseman; Martha Q. Lacy; Suzanne R. Hayman; Shaji 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame

Post-transplant outcomes of induction th

Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support

✍ Dan T. Vogl; Stephen V. Liu; Elise A. Chong; Selina M. Luger; David L. Porter; S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 2 views

High-dose therapy and autologous periphe

High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients

✍ Massimo Martino; Giuseppe Console; Giuseppe Irrera; Giulia Praticò; Caterina Ste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 2 views

## Abstract The recent development of reduced intensity conditioning and allotransplantation (RICT) has opened a new way to assure engraftment of donor cells while reducing early transplant‐related mortality. We evaluated the combination of high‐dose therapy and autologous peripheral blood stem cel